Insilico Announces Strategic Collaboration for AI-Based Drug Discovery
The new collaboration leverages Insilico’s end-to-end discovery platform and EQRx’s innovative business model to accelerate drug development.
Insilico Medicine has announced that it has entered into a strategic collaboration with EQRx, a drug discovery company committed to developing and delivering innovative medicines to patients at “drastically lower prices”.
The collaboration will combine Insilico’s Pharma.AI platform to advance de novo design and generation of small molecules with the clinical development and commercialization expertise of EQRx. EQRx and Insilico will engage in a co-development partnership in which each party will be eligible for a share of the profits proportional to their respective level of investment.
Longevity.Technology: Before the rise of machine learning, drug discovery was expensive, time-consuming, and had a high attrition rate. As datasets grow and algorithms become more sophisticated, ML plays a greater role in drug discovery, all the way from target identification to clinical trial evaluation, as well as the evaluation of candidates for drug redirection. Insilico’s end-to-end, AI-powered Pharma.AI platform is dedicated to the discovery of new small molecule drug candidates for multiple targets; the new partnership with EQRx takes this discovery to the next level – in the clinic. Moreover, the main driver of the collaboration is accessibility, the manufacture of innovative medicines that are affordable and effective.
Pursuant to the collaboration agreement, the parties will identify and select up to three therapeutic targets leveraging Insilico’s AI-based platform, Pharma.AI. Insilico will lead drug discovery from identification of small molecules to optimization of leads and nomination of preclinical candidates to Investigational New Drug (IND) application. EQRx will assume responsibility for driving clinical development, regulatory activities and commercialization. Insilico has the option to invest in product candidate(s) at various stages of clinical development in return for increased commercialization profits.
“EQRx and Insilico Medicine are working to accelerate the discovery and development of new drugs and to make effective treatments more accessible and affordable,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “This partnership will combine our end-to-end AI-based drug discovery capabilities with EQRx’s innovative partnership model and expertise in clinical development and patient access to accelerate discovery and development. innovative therapies. .”
“We are thrilled to partner with Insilico Medicine, a leader in AI-based drug discovery,” said Carlos Garcia-Echeverria, PhD, Head of Rx Creation at EQRx. “This collaboration will further expand our early-stage R&D efforts to fuel potential pipeline growth as we continue to apply the best of today’s innovation in biomedical sciences and digital solutions to discover high-quality, innovative medicines. and more affordable. .”